Prostate cancer detection after atypical small acinar proliferation (ASAP): A 10-year single-centre cohort
- PMID: 39323925
- PMCID: PMC11420094
- DOI: 10.1002/bco2.407
Prostate cancer detection after atypical small acinar proliferation (ASAP): A 10-year single-centre cohort
Erratum in
-
Erratum.BJUI Compass. 2024 Dec 30;5(12):1324-1329. doi: 10.1002/bco2.482. eCollection 2024 Dec. BJUI Compass. 2024. PMID: 39744071 Free PMC article.
Keywords: ASAP; atypical small acinar proliferation; biopsy; prostate cancer.
Conflict of interest statement
Lisa Browning receives funding for a study (ArticulatePro) evaluating Paige Prostate, which is funded by the NHSX Artificial Intelligence in Health and Care Award: Driving system‐wide improvements with real‐world economics evidence and subspecialist‐led adoption guidelines for full workflow implementation of AI with Paige Prostate cancer detection (Paige AI 2020, New York), grading and quantification tool in histopathology departments (AI_AWARD02269). Richard Colling is part funded by UKRI (WCT WVI MAP project and PathLAKE project in‐kind partnership with Philips), mdxhealth (research funding), NHSX (ARTICULATE PRO: evaluating Paige AI), and the Clarendon Fund (University of Oxford). Richard Bryant receives grant funding for TRANSLATE Trial (NIHR‐HTA: NIHR131233), PART Trial Funding (NIHR‐HTA: 17/150/01), Cancer Research Clinician Scientist Fellowship (A22748). Participates in STAMINA Trial Programme Steering Committee. Ian Roberts receives consulting fees from Novartis and Travere Therapeutics and support for attending meetings from American Society of Nephrology, International Academy of Pathology and Asia Pacific Society of Nephrology. Alastair Lamb receives grant funding for TRANSLATE Trial (NIHR‐HTA: NIHR131233). ADL was supported by a Cancer Research UK Clinician Scientist Fellowship award (C57899/A25812).
Similar articles
-
Prostate cancer detection following diagnosis of atypical small acinar proliferation.Can J Urol. 2017 Apr;24(2):8714-8720. Can J Urol. 2017. PMID: 28436357
-
Rate of clinically significant prostate cancer on repeat saturation biopsy after a diagnosis of atypical small acinar proliferation.Urologia. 2021 Aug;88(3):194-199. doi: 10.1177/0391560321993595. Epub 2021 Feb 12. Urologia. 2021. PMID: 33579180
-
Atypical small acinar proliferation (ASAP) on extended prostatic biopsies: predictive factors of cancer detection on repeat biopsies.Arch Ital Urol Androl. 2005 Mar;77(1):31-6. Arch Ital Urol Androl. 2005. PMID: 15906787
-
Atypical small acinar proliferation (ASAP): Is a repeat biopsy necessary ASAP? A multi-institutional review.Prostate Cancer Prostatic Dis. 2016 Mar;19(1):68-71. doi: 10.1038/pcan.2015.52. Epub 2015 Nov 17. Prostate Cancer Prostatic Dis. 2016. PMID: 26857145 Review.
-
The Rate of Clinically Significant Prostate Cancer on Repeat Biopsy after a Diagnosis of Atypical Small Acinar Proliferation: A Systematic Review and Meta-Analysis.Oncology. 2024;102(7):631-640. doi: 10.1159/000535123. Epub 2023 Dec 7. Oncology. 2024. PMID: 38061334
Cited by
-
Erratum.BJUI Compass. 2024 Dec 30;5(12):1324-1329. doi: 10.1002/bco2.482. eCollection 2024 Dec. BJUI Compass. 2024. PMID: 39744071 Free PMC article.
References
-
- Norman RD, Garg H, Rickborn L, Kaushik D, Pruthi DK, Mansour AM, et al. Clinically significant prostate cancer in men with high‐grade intraepithelial prostatic intraepithelial neoplasia or atypical small acinar proliferation. JU Open Plus. 2023;1(9). 10.1097/ju9.0000000000000050 - DOI
-
- EAU guidelines. Edn. presented at the EAU Annual Congress Amsterdam 2022. ISBN 978‐94‐92671‐16‐5.
LinkOut - more resources
Full Text Sources